News, views and contacts from the global Pharmaceutical industry
 

News Archive

Archive of industry news from the global pharmaceutical industry

News By Date

August 2015

Top

Boehringer and Eli Lilly receive FDA approval for Synjardy to treat type 2 diabetes
28 August 2015 Boehringer Ingelheim Pharmaceuticals and Eli Lilly have received approval from the US Food and Drug Administration (FDA) for Synjardy (empagliflozin and metformin hydrochloride) tablets to...

Celgene acquires biopharmaceutical firm Receptos for $7.2bn
28 August 2015 US-based Celgene has completed the acquisition of biopharmaceutical firm Receptos, for...

Sucampo to acquire Japan’s R-Tech Ueno for $278m
27 August 2015 Sucampo Pharmaceuticals has agreed to acquire Japan-based pharmaceutical firm R-Tech Ueno for around JPY33bn...

Novo Nordisk to develop $2bn new production facilities in US and Denmark
27 August 2015 Healthcare firm Novo Nordisk has unveiled plans to invest around $2bn to develop new production facilities in the US and Denmark, in a bid to meet the increasing demand for its diabetes...

MorphoSys, Immatics collaborate to develop antibody-based therapeutics for solid cancers
26 August 2015 MorphoSys has partnered with Immatics Biotechnologies to develop novel antibody-based therapeutics against multiple proprietary cancer antigens differentiated by T...

Mayo Clinic researchers reprogramme cancer cells back to normal
26 August 2015 Researchers from Mayo Clinic in the US have discovered a new way to reprogramme cancer cells back to normal, minimising the tumour...

Exelixis’ cabozantinib gets FDA breakthrough therapy status for renal cell carcinoma
25 August 2015 Biopharmaceutical firm Exelixis has received breakthrough therapy designation from the US Food & Drug Administration (FDA) for its cabozantinib to treat patients with advanced renal cell...

NHS England recommends Janssen’s Situro to treat MDR-TB in adult patients
25 August 2015 NHS England has issued a new clinical commissioning policy, which approved Janssen's Situro to treat pulmonary multi-drug resistant tuberculosis (MDR-TB) in adult...

Seres receives FDA orphan drug status for SER-109 to prevent CDI in adults
24 August 2015 Seres Therapeutics has obtained orphan drug status from the US Food and Drug Administration (FDA) for its SER-109 to prevent recurrent Clostridium difficile infection (CDI) in...

Novartis purchases remaining rights of cancer drug Ofatumumab from GSK for $1bn
24 August 2015 Switzerland-based Novartis has signed an agreement with British drugmaker GlaxoSmithKline (GSK) to purchase all remaining rights of Ofatumumab, for around...

Cancer patients miss out on personalised treatments in England: Cancer Research UK
21 August 2015 A new report commissioned by Cancer Research UK has revealed that thousands of cancer patients in England are not being given a test to see if drugs might benefit them, due to which they...

Cempra’s solithromycin receives FDA fast track designation to treat CABP
21 August 2015 Clinical-stage pharmaceutical firm Cempra has obtained fast track designation from the US Food and Drug Administration (FDA) for solithromycin intravenous (IV) and capsules to treat...

FDA grants fast track status to Corbus’ Resunab to treat systemic sclerosis
20 August 2015 Corbus Pharmaceuticals Holdings has received fast track status from the US Food and Drug Administration (FDA) for its investigational drug Resunab to treat systemic sclerosis...

Valeant plans to acquire ‘female Viagra’ Addyi drugmaker Sprout for $1bn
20 August 2015 Canada-based Valeant Pharmaceuticals International is reportedly planning to acquire US-based 'female Viagra' Addyi drugmaker Sprout Pharmaceuticals for around...

Pfenex receives $143.5m contract to develop new anthrax vaccine
19 August 2015 US-based Pfenex has received a $143.5m five-year contract from the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS) to...

Sprout’s Addyi obtains FDA approval to treat sexual dysfunction in women
19 August 2015 Sprout Pharmaceuticals has obtained approval from the US Food and Drug Administration (FDA) for its Addyi (flibanserin 100mg) to treat acquired, generalised hypoactive sexual desire disorder...

Novartis and Aveo Oncology partner to develop AV-380 and related antibodies
18 August 2015 US-based Aveo Oncology has entered an exclusive and worldwide licence agreement with Swiss drugmaker Novartis to develop and commercialise AV-380 and related antibodies, including modified...

AMAG Pharmaceuticals acquires Cord Blood Registry for $700m
18 August 2015 US-based AMAG Pharmaceuticals has completed the acquisition of umbilical cord blood stem cell collection and storage firm Cord Blood Registry (CBR) for $700m....

Novo Nordisk to use Genmab’s DuoBody technology to develop bispecific antibodies
17 August 2015 Novo Nordisk has licensed Genmab’s DuoBody technology platform to create and develop bispecific antibody candidates for two therapeutic programmes....

Baxter and Water Street’s Cefazolin Injection 2gm premix obtains FDA approval
17 August 2015 Baxter International and Water Street Healthcare have received approval from the US Food and Drug Administration (FDA) for Cefazolin Injection in Galaxy container...

China’s WuXi PharmaTech signs $3.3bn merger agreement
14 August 2015 Research and development firm WuXi PharmaTech (Cayman) has signed a definitive merger agreement with New WuXi Life Science and its wholly owned subsidiary WuXi Merger....


cachename:Newscachekey:rd-1665407042_1857678299_rd-488908060_1243308781_ap1243308781_1857678299_874850511